Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

C Riccay Elizondo

2PUBLICATIONS
3CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

Sort by Publication Date:
|Sep 07, 2022
Vaccination with a shared oncogenic tumor-self antigen elicits a population of CD8+ T cells with a regulatory phenotype.

C Riccay Elizondo, Jennifer D Bright, Robert K Bright

|Nov 27, 2019
Analysis of the CD8+ IL-10+ T cell response elicited by vaccination with the oncogenic tumor-self protein D52.

C Riccay Elizondo, Jennifer D Bright, Jennifer A Byrne

Pageof 1

Frequent Collaborators

2 joint publications

Jennifer D Bright

2 joint publications

Robert K Bright

1 joint publications

Jennifer A Byrne

Frequent Collaborators

2 joint publications

Jennifer D Bright

2 joint publications

Robert K Bright

1 joint publications

Jennifer A Byrne

Top Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses

Published on : May 06, 2019

9.1K
See more related videos

Top Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8<sup>+</sup> T Cell Responses

Published on : May 06, 2019

9.1K
See more related videos